{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05961839",
            "orgStudyIdInfo": {
                "id": "SGR-2921-101"
            },
            "organization": {
                "fullName": "Schr\u00f6dinger, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",
            "officialTitle": "A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",
            "therapeuticArea": [
                "Rare Diseases",
                "Oncology and Hematology"
            ],
            "study": "study-of-sgr-in-relapsed-refractory-acute-myeloid-leukemia-or-myelodysplastic-syndrome"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-27",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-07-17",
            "studyFirstSubmitQcDate": "2023-07-17",
            "studyFirstPostDateStruct": {
                "date": "2023-07-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-18",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-20",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Schr\u00f6dinger, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.",
            "detailedDescription": "This is a study of SGR-2921, an oral, small molecule inhibitor of cell division cycle 7-related protein kinase (CDC7), in subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.\n\nExploratory cohorts may evaluate additional PK, PD, preliminary anti-tumor activity, and safety to establish the SGR-2921 RD. A planned amendment will evaluate SGR-2921 in combination with other approved AML/MDS treatments such as hypomethylating agents (HMA), BCL2 inhibitors, IDH inhibitors or FLT3 inhibitors, in patients with AML and/or MDS."
        },
        "conditionsModule": {
            "conditions": [
                "Acute Myeloid Leukemia",
                "High-Risk and Very High-Risk Myelodysplastic Syndromes"
            ],
            "keywords": [
                "MDS",
                "Relapsed or Refractory AML"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Escalation in the Absence of Specific Azole Antifungal Treatments",
                    "type": "EXPERIMENTAL",
                    "description": "Up to 9 dose levels will be evaluated in subjects not receiving specific azole antifungal treatment.",
                    "interventionNames": [
                        "Drug: SGR-2921"
                    ]
                },
                {
                    "label": "Dose Escalation in the Presence of Specific Azole Antifungal Treatments",
                    "type": "EXPERIMENTAL",
                    "description": "Up to 9 dose levels will be evaluated in subjects receiving specific azole antifungal treatment.",
                    "interventionNames": [
                        "Drug: SGR-2921"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "SGR-2921",
                    "description": "SGR-2921 will be administered orally.",
                    "armGroupLabels": [
                        "Dose Escalation in the Absence of Specific Azole Antifungal Treatments",
                        "Dose Escalation in the Presence of Specific Azole Antifungal Treatments"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Dose Limiting Toxicities",
                    "timeFrame": "From first dose until the end of Cycle 1 (approximately 28 days, up to 42 days)."
                },
                {
                    "measure": "Adverse Events",
                    "description": "Incidence, nature, and severity of adverse events (AEs) as assessed by the NCI CTCAE v5.0.",
                    "timeFrame": "Throughout the study, up to 26 months."
                },
                {
                    "measure": "Electrocardiograms in Singlicate and Triplicate",
                    "description": "Uncorrected QT interval, QTcF, PR duration, QRS interval, and RR interval.",
                    "timeFrame": "Throughout the study, up to 26 months."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "SGR-2921 Maximal Plasma Concentration (Cmax)",
                    "description": "Concentrations of SGR-2921 in plasma are measured at various timepoints following its administration to calculate typical exposure/PK parameters, including, but not limited to, the maximal plasma concentration (Cmax).",
                    "timeFrame": "Throughout the study, up to 26 months."
                },
                {
                    "measure": "SGR-2921 Minimum Plasma Concentration (Cmin)",
                    "description": "Concentrations of SGR-2921 in plasma are measured at various timepoints following its administration to calculate typical exposure/PK parameters, including, but not limited to, the minimum plasma concentration (Cmin).",
                    "timeFrame": "Throughout the study, up to 26 months."
                },
                {
                    "measure": "SGR-2921 Time to Maximal Plasma Concentration (tmax)",
                    "description": "Concentrations of SGR-2921 in plasma are measured at various timepoints following its administration to calculate typical exposure/PK parameters, including, but not limited to, the time to maximal plasma concentration (tmax).",
                    "timeFrame": "Throughout the study, up to 26 months."
                },
                {
                    "measure": "SGR-2921 Area Under the Concentration Versus Time Curve (AUC)",
                    "description": "Concentrations of SGR-2921 in plasma are measured at various timepoints following its administration to calculate typical exposure/PK parameters, including, but not limited to, the area under the concentration versus time curve (AUC).",
                    "timeFrame": "Throughout the study, up to 26 months."
                },
                {
                    "measure": "Composite Complete Remission (CR) Rate for Subjects with AML",
                    "description": "The percentage of subjects with CR, CR with Partial Hematologic Recovery (CRh), and CR with Incomplete Blood Count Recovery (CRi).",
                    "timeFrame": "Throughout the study, up to 26 months."
                },
                {
                    "measure": "Objective Response Rate (ORR) for Subjects with AML",
                    "description": "The percentage of subjects achieving CR, CRh, CRi, morphologic leukemia-free state (MLFS) and Partial Response (PR).",
                    "timeFrame": "Throughout the study, up to 26 months."
                },
                {
                    "measure": "Objective Response Rate (ORR) for Subjects with MDS",
                    "description": "The percentage of subjects achieving CR and PR.",
                    "timeFrame": "Throughout the study, up to 26 months."
                },
                {
                    "measure": "Duration of Response (DOR) for Subjects with AML",
                    "description": "The time from first response (CR, CRh, CRi, MLFS, or PR) to the date of initial objectively documented progression or death due to any cause, whichever occurs first.",
                    "timeFrame": "Throughout the study, up to 26 months."
                },
                {
                    "measure": "Duration of Response (DOR) for subjects with MDS",
                    "description": "The time from first response (CR or PR) to the date of initial objectively documented progression or death due to any cause, whichever occurs first.",
                    "timeFrame": "Throughout the study, up to 26 months."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* \u2265 18 years of age.\n* Life expectancy \u2265 8 weeks.\n* Confirmed diagnosis of R/R AML or High Risk (HR) and Very High Risk (VHR) MDS.\n* Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2.\n\nExclusion Criteria:\n\n* Active malignancies within two years prior to the first dose, or requiring ongoing treatment, not related to AML or MDS.\n* Clinical evidence of central nervous system (CNS) or pulmonary leukostasis, \u2265 Grade 3 disseminated intravascular coagulation, or active CNS leukemia.\n* Use of experimental drug, or therapy, or anti-cancer therapy within 14 days or 5 half-lives of the first dose of study drug.\n* QT interval corrected for heart rate per Fridericia's formula \u2265470 msec during screening ECG.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Physician",
                    "role": "CONTACT",
                    "phone": "+15032991150",
                    "email": "sdgr-trials-group@schrodinger.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Daniel Weiss, M.D.",
                    "affiliation": "Schr\u00f6dinger, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Colorado Blood Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Marcello Rotta, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Roswell Park Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14263",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Eunice Wang, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Eytan Stein, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Cleveland Clinic Foundation",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Hetty Carraway, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "The Ohio State University Wexner Medical Center - James Cancer Hospital",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43210",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alice Mims, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                },
                {
                    "facility": "Oncology Associates of Oregon, P.C.",
                    "status": "RECRUITING",
                    "city": "Eugene",
                    "state": "Oregon",
                    "zip": "97401",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Luke Fletcher, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.05207,
                        "lon": -123.08675
                    }
                },
                {
                    "facility": "Oregon Health & Science University - Knight Cancer Institute - Center of Hematologic Malignancies",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Elie Traer, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19107",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gina Keiffer, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "TriStar Bone Marrow Transplant, LLC",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Steven Strickland, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "St. David's South Austin Medical Center",
                    "status": "RECRUITING",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78745",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Aravind Ramakrishnan, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Courtney DiNardo, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000007951",
                    "term": "Leukemia, Myeloid"
                },
                {
                    "id": "D000015470",
                    "term": "Leukemia, Myeloid, Acute"
                },
                {
                    "id": "D000011289",
                    "term": "Preleukemia"
                },
                {
                    "id": "D000009190",
                    "term": "Myelodysplastic Syndromes"
                },
                {
                    "id": "D000013577",
                    "term": "Syndrome"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004194",
                    "term": "Disease"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                },
                {
                    "id": "D000011230",
                    "term": "Precancerous Conditions"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "asFound": "Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18127",
                    "name": "Leukemia, Myeloid, Acute",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14164",
                    "name": "Preleukemia",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12145",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14111",
                    "name": "Precancerous Conditions",
                    "relevance": "LOW"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T182",
                    "name": "Acute Myeloid Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T188",
                    "name": "Acute Non Lymphoblastic Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3993",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M6252",
                    "name": "Clotrimazole",
                    "relevance": "LOW"
                },
                {
                    "id": "M11796",
                    "name": "Miconazole",
                    "relevance": "LOW"
                },
                {
                    "id": "M4254",
                    "name": "Antifungal Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}